Literature DB >> 30711460

Depression and Antidepressants as Potential Risk Factors in Dementia: A Systematic Review and Meta-analysis of 18 Longitudinal Studies.

Joyce Y C Chan1, Karen K L Yiu2, Timothy C Y Kwok1, Samuel Y S Wong3, Kelvin K F Tsoi4.   

Abstract

OBJECTIVE: To investigate whether depression and/or antidepressants can be a potential risk factor for the development of dementia and mild cognitive impairment (MCI).
DESIGN: Systematic review and meta-analysis of longitudinal studies. SETTING AND PARTICIPANTS: Community or clinical settings. Participants included patients with depression, antidepressant users, and the general population. MEASURES: Longitudinal studies evaluating the risks of dementia or MCI in patients with depression and/or antidepressant users were identified from the OVID database. The outcomes were the number of patients who developed dementia or MCI among the antidepressant users and nonusers. Relative risk (RR) with 95% confidence interval (95% CI) was used to evaluate the association between the use of antidepressants and the risk of dementia and MCI. Meta-analysis was used for combining the effect sizes of individual studies, and the heterogeneity test was performed. Risk of bias and reporting quality of included studies was assessed. Subgroup analyses were conducted for different types of antidepressants.
RESULTS: A total of 18 studies with 2,119,627 participants with mean age ranging from 55 to 81 years were included. Among patients with depression, antidepressant users showed a significantly higher risk of dementia (RR = 1.37, 95% CI = 1.11-1.70) and MCI (RR = 1.20, 95% CI = 1.02-1.42) than the nonusers. Besides, patients with depression who used antidepressants and who did not use antidepressants also showed significantly higher risk of dementia than the general population (RR = 1.50, 95% CI = 1.26-1.78, and RR = 1.31, 95% CI = 1.15-1.51, respectively). CONCLUSIONS/IMPLICATIONS: Patients with depression are associated with a higher risk of dementia, and the use of antidepressants is not shown to be a protective factor of dementia. Further large-scale trials are required for investigation of the benefit-risk ratio between depression relapse and dementia when prescribing antidepressants.
Copyright © 2018 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressants; dementia; depression; mild cognitive impairment

Mesh:

Substances:

Year:  2019        PMID: 30711460     DOI: 10.1016/j.jamda.2018.12.004

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  5 in total

1.  Depression and Increased Risk of Alzheimer's Dementia: Longitudinal Analyses of Modifiable Risk and Sex-Related Factors.

Authors:  Doyoung Kim; RuoDing Wang; Alex Kiss; Susan E Bronskill; Krista L Lanctot; Nathan Herrmann; Damien Gallagher
Journal:  Am J Geriatr Psychiatry       Date:  2021-01-06       Impact factor: 7.996

2.  Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia.

Authors:  Tau Ming Liew
Journal:  Alzheimers Res Ther       Date:  2020-03-31       Impact factor: 6.982

3.  Modifiable Risk Factor Possession Patterns of Dementia in Elderly with MCI: A 4-Year Repeated Measures Study.

Authors:  Osamu Katayama; Sangyoon Lee; Seongryu Bae; Keitaro Makino; Yohei Shinkai; Ippei Chiba; Kenji Harada; Hiroyuki Shimada
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

Review 4.  Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives.

Authors:  Lina Ma
Journal:  Front Aging Neurosci       Date:  2020-01-30       Impact factor: 5.750

5.  The Prevalence of Amnestic and Non-Amnestic Mild Cognitive Impairment and Its Association with Different Lifestyle Factors in a South Italian Elderly Population.

Authors:  Alessandro Oronzo Caffò; Giuseppina Spano; Luigi Tinella; Antonella Lopez; Elisabetta Ricciardi; Fabrizio Stasolla; Andrea Bosco
Journal:  Int J Environ Res Public Health       Date:  2022-03-06       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.